| 摘要 |
<p>#CMT# #/CMT# Antibody, preferably monoclonal antibody, which is selectively or specifically interacted, preferably bonded, with at least one carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) protein; the interaction, preferably binding, of the antibody takes place in the region of an A-domain and/or in the region of a B-domain of the CEACAM1 protein, preferably in the A-domain and/or B-domain of the CEACAM1 protein; and/or the interaction, preferably binding, of the antibody is not performed in an N-domain of the CEACAM1 protein, is new. #CMT# : #/CMT# Independent claims are included for: (1) antibody-producing and/or antibody-releasing cells, preferably hybridoma cells; (2) producing cells, preferably hybridoma cells, comprising (a1) providing an immunogen and/or antigen based on CEACAM1 protein truncated at N-terminal end, preferably a truncated CEACAM1 protein with at least partially missing N-domain, preferably with at least completely missing N-domain, (b1) treating and/or immunizing an animal, particularly a mouse, preferably a Balb/c-mouse with the immunogen and/or antigen provided in step (a1), (c1) obtaining and/or isolating the antibody-producing immune cells, particularly splenocytes, preferably B-lymphocytes of the animals treated and/or immunized in step (b1), (d1) blending and/or merging the immune cells obtained in step (c1) with cells of an immortalized cell line, preferably myeloma cells, to hybridoma cells, and (e1) optionally increasing, preferably cloning, the hybridoma cells obtained in step (d1); (3) use of a truncated and/or inactivated adhesion molecule, preferably adhesion protein, with at least partially missing adhesion domain and/or with at least partially missing N-domain, preferably with at least substantially completely missing adhesion domain and/or preferably at least substantially completely missing N-domain, for diagnosis and/or prognosis of cancer, preferably cancer of the urinary tract, particularly prostate cancer and/or bladder cancer; (4) detecting and/or determining a truncated CEACAM1 protein with at least partially missing N-domain, preferably with at least substantially completely missing N-domain, in a sample, comprising providing the sample, contacting the sample with an antibody, identifying and/or detecting a specific and/or selective binding and/or interaction of the antibody with the truncated CEACAM1 protein, optionally quantitatively determining the content and/or the amount of the truncated CEACAM1 protein in the sample by correlating the amount and/or the content of the truncated CEACAM1 protein with the binding and/or interaction; (5) a composition comprising the antibody; and (6) a kit for specific and/or selective detection and/or determination of CEACAM1 protein in a sample, comprising the antibody or composition. #CMT#USE : #/CMT# The antibody is useful for the specific and/or selective determination and/or detection of CEACAM1 protein in a sample; for the diagnosis and/or prognosis of a truncated CEACAM1 protein related diseases, preferably cancer, which is cancer of the urinary tract, preferably prostate cancer and/or bladder cancer (all claimed). #CMT#BIOLOGY : #/CMT# Preparation: Preparation of antibody comprises cloning a CEACAM1-deltaN optionally with an Fc-peptide and/or a signal peptide, preferably rat signal peptide, followed by antigen expression and purifying the antigens via an affinity chromatography. Preferred Components: The CEACAM1 protein is: a human CEACAM1 protein; native CEACAM1 protein; an isoform, preferably splice variant; a truncated CEACAM1 protein, preferably CEACAM1-protein truncated at N-terminal end; or a truncated CEACAM1 protein with at least partially missing N-domain, preferably at least completely missing N-domain. The A-domain of the CEACAM1 protein is an A1-domain and/or the B domain of the CEACAM1 protein is a B1 domain; the A domain, preferably the A1 domain is arranged in a protein section of the CEACAM1 protein; the protein section contains the amino acid sequence from position 158-234, relative to the complete CEACAM1 protein and starting in the counting at the N-terminal end of the protein. The antibody is of murine origin; the antibody is produced by hybridoma cell, where the hybridoma cells are originated from the fusion of cells of an immortalized cell line, preferably myeloma cells, with the antibody-producing immune cells, particularly splenocytes, preferably B lymphocytes; the antibody-producing immune cells (experimental) animals, particularly mice, preferably Balb/c-mice are isolated, where the (experimental) animals are treated and/or immunized before with an immunogen based on an N-terminal end truncated CEACAM1 protein, preferably a truncated CEACAM1 protein with at least partial absence of N-domain, preferably with at least completely missing N-domain. The antibody has monoclonal antibody (mAb) B3 and mAb C5-1X and/or the antibody is produced and/or released from a cell culture, preferably hybridoma cells, which are deposited under the accession number DSM ACC3051 and DSM ACC3052 and the filing date 24, March 2010 at the German Collection of Microorganisms and Cell Cultures according to the Budapest Treaty. #CMT#EXAMPLE : #/CMT# No suitable example given.</p> |
